Turning Point Therapeutics, an early stage biotech developing tyrosine kinase inhibitors for cancer treatment, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The San Diego, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol TPTX. Turning Point Therapeutics filed confidentially on February 14, 2019. Goldman Sachs, SVB Leerink and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
